Lilly to buy AtaiBeckley for USD 6.75 per share plus CVR up to USD 2.5 - LLY News | RalliesLilly to buy AtaiBeckley for USD 6.75 per share plus CVR up to USD 2.5
L
LLY• Lilly agrees to acquire AtaiBeckley
- Eli Lilly agreed to buy AtaiBeckley for USD 6.75 a share in cash, valuing the equity at about USD 2.8 billion.
- The deal includes a contingent value right of up to USD 2.5 a share tied to development and U.S. approval milestones for BPL-003 and VLS-01.
- AtaiBeckley’s lead asset, BPL-003, an intranasal synthetic 5-MeO-DMT, is in Phase 3 activities for treatment-resistant depression.
- The transaction is expected to close in the third quarter, pending AtaiBeckley shareholder vote and regulatory clearances.
- The offer represents about a 40% premium to AtaiBeckley’s 30-day volume-weighted average price through July 15, 2026.
FRMM
•
